Inhibition of Aldosterone in Patients With Chronic Renal Disease

This study has been completed.
Rigshospitalet, Denmark
Information provided by (Responsible Party):
Lene Boesby, Herlev Hospital Identifier:
First received: February 1, 2007
Last updated: February 7, 2012
Last verified: February 2012
The purpose of this study is to examine whether the inhibition of aldosterone will result in lower excretion of protein via urine. The hypothesis is that if loss of protein is lowered, progression of renal disease with be slower than otherwise expected.

Condition Intervention Phase
Kidney Failure, Chronic
Drug: Eplerenone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease

Resource links provided by NLM:

Further study details as provided by Herlev Hospital:

Primary Outcome Measures:
  • Proteinuria reduction [ Time Frame: bi-monthly ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluating blood pressure response and hyperkalaemia after aldosterone inhibition. [ Time Frame: weekly ] [ Designated as safety issue: Yes ]

Enrollment: 42
Study Start Date: March 2007
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Drug: Eplerenone
Once daily administration for 8 weeks and 8 weeks control.
No Intervention: 2
Drug: Eplerenone
Once daily administration for 8 weeks and 8 weeks control.

Detailed Description:

Patients with chronic renal disease are likely to progress to end stage renal disease with the need for renal replacement therapy. It is accepted that proteinuria is a surrogate measurement for progression. If proteinuria can be lowered we hope to prolong patients pre-dialysis phase. Our theory is that aldosterone inhibition will lead to this.

For a period of 8 weeks patients will be randomized to either aldosterone receptor inhibition with the drug eplerenone or control without. Blood pressures will be kept at the same level using other drugs.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Proteinuria > 500 mg/24 hours
  • Hypertension or anti-hypertensive treatment

Exclusion Criteria:

  • Diabetic nephropathy
  • GFR< 20 ml/min
  • P-potassium between 3,5 mmol/l and 5,0 mmol/l
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00430924

Rigshospitalet, Blegdamsvej 9
Copenhagen, Denmark, DK-2100 Ø
Herlev Hospital
Herlev, Denmark, DK-2730
Sponsors and Collaborators
Lene Boesby
Rigshospitalet, Denmark
Study Director: Svend Strandgaard, DMSc
Study Director: Anne-Lise Kamper, DMSc nonaffiliated
  More Information

Additional Information:
No publications provided by Herlev Hospital

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lene Boesby, MD, Herlev Hospital Identifier: NCT00430924     History of Changes
Other Study ID Numbers: B109LB1  2006-004411-21 
Study First Received: February 1, 2007
Last Updated: February 7, 2012
Health Authority: Denmark: Danish Medicines Agency
Denmark: Danish Dataprotection Agency
United States: Food and Drug Administration
Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by Herlev Hospital:
Kidney Failure, Chronic
Renin-Angiotensin System

Additional relevant MeSH terms:
Kidney Failure, Chronic
Renal Insufficiency
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Cardiovascular Agents
Diuretics, Potassium Sparing
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Mineralocorticoid Receptor Antagonists
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 09, 2016